BiomX Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BiomX Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.20M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($17.73M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($26.17M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($28.32M) | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | ($36.23M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($30.09M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($20.56M) | Mar 31, 2021 |
| FY2019 | Jun 30, 2019 | $347.4K | Aug 21, 2019 |
| FY2019 | Dec 31, 2018 | ($12.72M) | Mar 26, 2020 |
| FY2019 | Jun 30, 2018 | ($1.0K) | Aug 21, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.47M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($44.52M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($25.35M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($27.22M) | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | ($35.46M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($30.26M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($22.21M) | Mar 31, 2021 |
| FY2019 | Jun 30, 2019 | ($404.5K) | Aug 21, 2019 |
| FY2019 | Dec 31, 2018 | ($12.50M) | Mar 26, 2020 |
| FY2019 | Jun 30, 2018 | ($1.0K) | Aug 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.29M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $24.66M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $16.70M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $16.24M | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | $22.68M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $19.42M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $13.49M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $9.14M | Mar 26, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.39M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($36.98M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($21.29M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($29.09M) | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | ($27.57M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($24.45M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($17.58M) | Mar 31, 2021 |
| FY2019 | Jun 30, 2019 | ($204.6K) | Aug 21, 2019 |
| FY2019 | Dec 31, 2018 | ($11.30M) | Mar 26, 2020 |
| FY2019 | Jun 30, 2018 | ($25) | Aug 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.0K | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $30.0K | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $50.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $112.0K | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | $3.68M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $1.01M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.31M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $137.0K | Mar 26, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.78M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $43.23M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $25.03M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $45.53M | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | $77.99M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $70.36M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $92.12M | Mar 31, 2021 |
| FY2019 | Jun 30, 2019 | $71.62M | Aug 21, 2019 |
| FY2019 | Dec 31, 2018 | $45.33M | Mar 26, 2020 |
| FY2019 | Jun 30, 2018 | $65.0K | Aug 21, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2019 | $871.0K | Aug 21, 2019 |
| FY2019 | Jun 30, 2018 | $41.0K | Aug 21, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.30M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $24.15M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.08M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $21.04M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $47.54M | Apr 4, 2024 |
| FY2022 | Dec 31, 2020 | $57.47M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $84.46M | Mar 30, 2022 |
| FY2019 | Jun 30, 2019 | $5.00M | Aug 21, 2019 |
| FY2020 | Dec 31, 2018 | $42.80M | Mar 31, 2021 |
| FY2019 | Jun 30, 2018 | $24.0K | Aug 21, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $801.0K | Feb 19, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($216.90M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($180.70M) | Feb 19, 2026 |
| FY2024 | Aug 8, 2024 | ($180.70M) | Mar 25, 2025 |
| FY2024 | Dec 31, 2023 | ($162.97M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($136.80M) | Apr 4, 2024 |
| FY2019 | Jun 30, 2019 | $346.4K | Aug 21, 2019 |
| FY2019 | Jun 30, 2018 | ($1.0K) | Aug 21, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.36M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $16.86M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $14.91M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $31.33M | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | $62.10M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $36.48M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $72.26M | Mar 31, 2021 |
| FY2019 | Jun 30, 2019 | $696.8K | Aug 21, 2019 |
| FY2019 | Dec 31, 2018 | $8.60M | Mar 26, 2020 |
| FY2019 | Jun 30, 2018 | $430 | Aug 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $11.19M | Apr 4, 2024 |
| FY2022 | Dec 31, 2022 | $15.00M | Mar 29, 2023 |
| FY2021 | Dec 31, 2021 | $15.00M | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 25 | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 5 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | 1 | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 58 | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 5 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | 1 | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.59M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 1.02M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 4.72M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 29.98M | Apr 4, 2024 |
| FY2022 | Dec 31, 2021 | 29.75M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 23.26M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 22.86M | Mar 31, 2021 |
| FY2019 | Jun 30, 2019 | 2.24M | Aug 21, 2019 |
| FY2019 | Dec 31, 2018 | 2.31M | Mar 26, 2020 |
| FY2019 | Jun 30, 2018 | 2.01M | Aug 21, 2019 |